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Abstract: 
Dichloroacetate (DCA) is a synthetic compound that promotes the activity of pyruvate dehydrogenase (PDH) by inhibiting its repressor protein called 
pyruvate dehydrogenase kinase (PDHK). The activation of PDH leads to a reduction in ambient cellular lactate concentrations both in vitro and in vivo 
which contributes to the therapeutic use of DCA in the treatment of systemic lactic acidosis in humans. The therapeutic potential of DCA is now being 
explored in disorders that are accompanied by elevations of lactate concentration such as in hypoxic cancer cells. Yet conflicting evidence regarding its 
mutagenic potential has been a major setback in its clinical trials. Hence, docking and descriptor analysis of halogen substituted DCA analogues were 
performed to find out a drug candidate with less toxicity and better binding affinity than DCA. The Docking analysis was carried out using human PDHK 
isozyme 2, the physiological receptor for DCA. Bromo(iodo)acetate and Diiodoacetate were found out to be the plausible analogues of DCA from this 
study.  
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Abbreviations: DCA = Dichloroacetate, PDH = Pyruvate dehydrogenase, PDHK = Pyruvate dehydrogenase kinase. 
 
 
 
 
Background: 
Cancer development and its confrontation to chemotherapy depend, at least 
in part, on suppression of apoptosis. Although mitochondria are recognized 
as regulators of apoptosis, their importance as targets for cancer therapy 
has not been adequately explored or clinically exploited. Studies suggest 
that mitochondrial dysfunction in cancer cells may result in a characteristic 
aerobic glycolysis phenotype [1]. This bioenergetic feature is a good 
marker of cancer but has not been therapeutically pursued, as it is thought 
to be a result and not a cause of cancer; that is, the cells rely mostly on 
glycolysis for energy production because of permanent mitochondrial 
damage, preventing oxidative phosphorylation. It is also proposed that 
because early carcinogenesis occurs in a hypoxic microenvironment, the 
transformed cells initially have to rely on glycolysis for energy production 
[2]. However, this metabolic adaptation also appears to offer a proliferative 
advantage, suppressing apoptosis. Lactate formation during anaerobic 
glycolysis contributes to the breakdown of the extracellular matrix, 
facilitate cell mobility and increase the metastatic potential [3]. Many 
glycolytic enzymes have been recognized to also regulate apoptosis, and 
several oncoproteins induce the expression of glycolytic enzymes [4]. The 
switching in the metabolism of glucose to end with glycolysis in the 
cytoplasm by converting pyruvate to lactate or continue with glucose 
oxidation in the mitochondria is controlled by a gate-keeping 
mitochondrial enzyme, pyruvate dehydrogenase (PDH) which in turn is 
regulated by phosphorylation by PDH kinase (PDHK) [5]. 
 
Human PDHK has 4 isoforms which exhibit tissue-speciﬁc expression; 
PDHK1 is found in heart, pancreatic islets, and skeletal muscles; PDHK2 
is expressed in all tissues; PDHK3 is present in testes, kidney, and brain; 
and PDHK4 is profuse in heart, skeletal muscle, kidney, and pancreatic 
islets [6]. Preferential expression of PDHK might contribute to its cancer 
selectivity. In a study of lung cancer specimens, cancer cells had increased 
PDHK2 and decreased PDH expression (compatible with a glycolytic 
phenotype) compared to neighboring non-malignant cells [7]. Selective 
inactivation of PDHK isoforms by the speciﬁc inhibitor dichloroacetate has 
been shown to trigger apoptosis by promoting a mitochondrial potassium-
ion channel which inhibits tumor growth [5, 8].  
 
Dichloroacetate is effective in the treatment congenital lactic acidosis 
(CLA). People with CLA have defective PDH enzymes and are thus 
unable to efficiently produce energy. In one study, patients with CLA were 
treated with 25-50 mg of dichloroacetate per 1 kg of body weight. No 
major complications were observed in the participants [9]. However other 
side effects were observed somewhat frequently. These side effects varied 
in their presentation and severity, but all involved the central nervous 
system. Reversible neuropathy, or altered sensory or motor neuron 
function was the most common symptom observed. One study found that 
50% of patients treated with DCA developed this neuropathy causing the 
hindrance in pursuing further studies on using DCA for cancer therapy 
[10].  
 
Thus in order to find a less toxic analogue of DCA a series of halogen 
substitutions were tried and their binding energies, toxicity, C logP, mi 
logP, Drug score etc., were analyzed to sort out the better performing DCA 
analogues capable of inhibiting PDK. 
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Figure 1: Two dimensional structures of DCA and its halogen substituted analogues. 
 
Methodology: 
Receptor and ligands 
The three dimensional crystal structure of pyrvuate dehydrogenase kinase 
2 (PDB ID: 2BTZ) [11] was used as the receptor throughout the work and 
the two dimensional structures of the ligands were drawn using ACD 
chemsketch software [12]. The halogen substitutions using fluorine, iodine, 
bromine atoms were done on the DCA molecule with the following 
combinations DIA – Diiodoacetate, DFA – Difluoroacetate, DBrA – 
Dibromoacetate, CIA –Chloro(iodo)acetate, CFA – Chloro(fluoro)acetate, 
BrCA – Bromo(chloro)acetate, BrIA – Bromo(iodo)acetate, FIA – 
Fluoro(iodo)acetate and BrFA – Bromo(fluoro)acetate. The three 
dimensional structures of the ligands were obtained using the Dundee 
PRODRG tool [13]. 
 
Docking and descriptor analysis: 
The docking scores of the prepared ligands with PDHK2 receptor were 
determined using Argus lab software and Autodock Vina [14, 15]. The 
molecular descriptors such as C logP, mi logP, solubility, drug likeliness, 
Total Polar Surface Area (TPSA), molecular weight, volume, drug score, 
G-protein coupled receptors (GPCR) ligands, kinase inhibitor, ion channel 
modulator and nuclear receptor were obtained using Molinspiration [16] 
and OSIRIS Property explorer [17]. 
 
Toxicity prediction: 
The toxicity analysis such as Ames test, mutagenicity, tumorogenic, 
irritant, reproductive effective, mouse LD50 and oral bioavailabilty were 
obtained using ADME-TOX BOX of Pharma Algorithms [18].  
 
Results and Discussion: 
Docking analysis  
The Docking scores (Table 1 see supplementary material) were obtained 
from the analogues (Figure 1) with PDK2 as the receptor. The docking 
scores were the highest for DBrA with -7.47 Kcal/mol followed by BrIA -
7.36 Kcal/mol, CIA -7.32Kcal/mol, DIA with -7.27 Kcal/mol, DCA with -
7.19 Kcal/mol, BrCA with -7.17 Kcal/mol, DIA with -7.27 Kcal/mol, 
BrFA & CFA with -6.33 Kcal/mol,  FIA with -6.62 Kcal/mol and DFA 
with -5.88 Kcal/mol. 
 
Descriptor analysis: 
The descriptor analyses for the halogen substituted analogues of DCA are 
listed in Table 1 (see supplementary material). The C logP which 
measures the hydrophilicity of the molecule, favouring its entry through 
the lipid bilayer, indicated DFA with a low value of -0.44 followed by 
CFA with a score of 0.13. The solubility prediction showed DBrA with a 
high score of -1.44. Drug likeness was low for DIA (-1.97) and high for 
BrFA (16.6). The drug score indicated DIA with a high value of 0.53 
which is significantly higher than that of DCA with a value of 0.06. The 
score for kinase inhibition was high for BrFA (-4.15) and least for DCA (-
5.18). The score for Nuclear receptor ligand was high for CFA (-3.4) and 
least for DCA (-4.52). The mi logP was highest for DIA (1.554) followed 
by BrIA (1.28). The TPSA was found to be a constant for all the analogues 
with a value of 37.299. The GPCR ligand value was highest for BrFA (-
3.82) and low for DCA (-4.85). Finally the ion channel modulator score 
was high for CFA (-2.18) and low for DCA (-4.5). It was observed from 
the data that certain desirable parameters such as C logP, mi logP and drug 
score were potent for advocating DIA and BrIA as effective analogues for 
DCA. 
 
Toxicity prediction: 
The Toxicity characteristics of the DCA analogues are listed in Table 1 
(see supplementary material). The in silico studies on mutagenicity, 
tumorogenic, irritant and reproductive effective characteristics of DIA, 
DFA, BrIA, FIA and BrFA showed that they were in the safer levels. The 
Ames test values indicated DFA with a low value of 0.208 and BrIA with a 
high value of 0.517. The LD50 values in the intraperitonial, oral, 
intravenous and subcutaneous as 710, 1400, 260 and 900 mg/kg 
respectively for DCA followed by 410, 1100, 310 and 650 mg/kg 
respectively for BrIA. It is interesting to note that in both the low toxic 
analogues, DIA and BrIA, iodine is a constituent whose importance is 
required to make this discussion complete.  
 
Iodide is comparatively less toxic since nature has provided us with iodine 
metabolizing ability through thyroid gland. Studies have found an 
epidemiologic correlation between iodine deficiency, iodine-deficient 
goitre and gastric cancer [19]; a decrease of the incidence of death rate 
from stomach cancer after implementation of the effective iodine-
prophylaxis was reported with the proposed mechanism of action wherein 
the iodide ion functions in gastric mucosa as an 
antioxidant reducing species that can detoxify poisonous reactive oxygen 
species, such as hydrogen peroxide [20]. Further iodide moiety is more 
hydrophobic, which along with the overall small structure, compared to 
other anticancer drugs, makes the analogues an effective candidate to cross 
the blood brain barrier. 
 
Conclusion: 
The docking and toxicity analyses of DCA and its halogen substituted 
analogues showed that DIA and BrIA are effective in meeting the 
objectives of this study, namely low toxicity and high binding nature. Thus 
these analogues may be considered for further wet lab evaluation using in 
vitro and in vivo studies to develop an effective anti cancer drug.    
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Supplementry material: 
 
Table 1: Docking, molecular descriptor values & toxicity scores of DCA and its analogues. (R – Properties with high risks of undesired 
effects, O - Properties with moderate risk of undesired effects, G -Properties with drug-conform behaviour) 
 
Parameters/ Names  DCA  DIA  DFA  DBrA  CIA  CFA  BrCA  BrIA  FIA  BrFA 
Dock score using 
Auto dock vina 
(Kcal/mol) 
-4.1  -4.1  -4.2  -4.2  -4.2  -4.1  -4.2 -4.3 -4.2 -4.1 
Docking score using 
Argus lab(Kcal/mol) 
-7.19  -7.27  -5.88  -7.47  -7.32  -6.33  -7.17 -7.36 -6.62 -6.63 
Mutagenicity  R  G  G  G  R  R  R G G G 
Tumorogenic  R G  G R O  O R  G  G  G 
Irritant  R  G  G  G  O  O  O G G G 
Reproductive 
effective 
R  G  G  R  G  G  G G G G 
C logP  0.49  1.27  -0.44  0.59  0.88  0.13  0.54 0.93 0.52 0.18 
Solubility  -1.16  -0.6  -0.93  -1.44  -0.88  -1.07  -1.3 -1.02 -0.8 -1.22 
Molecular Weight  128  312  96 216  220  112  172 264 204 156 
Drug likeness  -3.82 -1.97  -9.89 -10.5  -3.6 -10.8 -12.9  -9.4  -8.87  -16.6 
Drug score  0.06  0.53  0.49  0.17  0.19  0.19  0.14 0.48 0.49 0.49 
Ames Test  0.463 0.48
9 
0.20
8 
0.576 0.46
4 
0.32
8 
0.514 0.517  0.32  0.37 
Intraperitoneal 
(mg/kg) 
710 330  179 160 210  340 400  410  120  83 
Oral (mg/kg)  1400  1100  430 620 730  660 920 1100 470  350 
Intravenous (mg/kg)  260 450  110 120 210  160 170  310  180  87 
Subcutaneous 
(mg/kg) 
900  560  160  290  370  390  580 650 180 130 
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Kinase inhibitor  -5.18  -4.42  -4.84  -4.52  -4.56  -4.21  -4.26 -4.49 -4.44 -4.15 
Nuclear receptor 
ligand 
-4.52  -3.83  -4.12  -4.14  -3.87  -3.4 -4.18 -4.48 -3.69 -4.01 
                  
mi log P  0.744 1.55
4 
0.12
8 
1.006 1.14
9 
0.43
6 
0.875 1.28 0.841  0.567 
TPSA  37.299 37.2
99 
37.2
99 
37.299 37.2
99 
37.2
99 
37.299 37.299 37.299 37.299 
Volume  83.536 104.
44 
66.3
27 
92.235 93.9
9 
74.9
31 
87.885 98.339 85.385 79.281 
GPCR ligand  -4.85  -4.09  -4.42  -4.26  -4.26  -3.83  -4.04 -4.26 -4.05 -3.82 
Ion channel 
modulator 
-4.5  -3.89  -4.11  -4.39  -3.98  -2.18  -4.09 -4.46 -3.81 -3.92 
 
 
 
 
 
 
 